TLDR:
- Foresite Capital closes its sixth fund with $900 million in capital commitments.
- The Fund VI targets precision therapeutics, life science infrastructure, and healthcare delivery in the healthcare and life sciences sector.
Summary:
San Francisco-based Foresite Capital has closed its sixth fund with $900 million in capital commitments. The fund targets precision therapeutics, life science infrastructure, and healthcare delivery in the healthcare and life sciences sector. Foresite Capital, founded in 2011, aims to address areas of unmet medical need by funding promising healthcare and life sciences businesses at all stages of their life cycles. The investment firm has a data and science-driven investment strategy, resulting in numerous successful IPOs, mergers and acquisitions, and FDA-approved drugs. Fund VI’s portfolio includes companies like Alumis, CG Oncology, Latigo, RayThera, Evonetix, and Xaira Therapeutics. Jim Tananbaum, founder and CEO, believes that the biotech investment environment is one of the best in his career. The fund’s limited partners comprise a wide range of investors, including university endowments, charitable foundations, and private banks.
